MedTrace Logo

Prospective Cohort Study on Thermal Ablation of Malignant Liver Tumors

NCT06179602 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2025-09-10

No results posted yet for this study

Summary

The endpoint of this study is to develop and validate algorithms, using artificial intelligence and machine learning, to optimize patient selection, treatment planning, treatment evaluation and outcome prediction in patients undergoing thermal ablation of a malignant liver tumor. The long-term objective is to establish thermal ablation as the treatment of choice for the vast majority of patients with a primary or secondary liver tumor by development of an accessible workflow that can be widely implemented in different centers performing thermal ablation. Over a time span of at least four years, data will be collected prospectively, encompassing patient information, tumor characteristics, and treatment details. Additionally, pre-, intra-, and post-procedural imaging will be systematically gathered.

Conditions

Sponsors & Collaborators

  • Philips Healthcare

    collaborator INDUSTRY

  • European Commission

    collaborator OTHER

  • Leiden University Medical Center

    lead OTHER

Principal Investigators

  • Mark C. Burgmans, MD PhD · Leiden univeristy medical centre

  • Christiaan van der Leij, MD PhD · Maastricht University Medical Centre

Eligibility

Min Age
18 Years
Max Age
110 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2027-12-15
Completion
2028-01-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06179602 on ClinicalTrials.gov